Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced that it will introduce a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day.

A higher pill burden has been associated with lower adherence to therapy, the latter affecting viral suppression and overall treatment outcomes. Also reducing the pill burden has been a demand from doctors and patients to enable adherence.

The 200 mg dosage of FabiFlu required patients to take 18 tablets on Day 1 (nine in the morning and nine in the evening), followed by 8 tablets each day thereafter for a maximum of 14 days. With the new 400 mg version, patients will now have a more relaxed dosage regimen, with 9 tablets required on Day 1( 4.5 in the morning and 4.5 in the evening), and thereafter 2 tablets twice a day from Day 2 till end of the course.

Dr Monika Tandon, vice president & head, clinical development, global specialty/branded portfolio, Glenmark Pharmaceuticals Ltd., said, “Being the first company to launch favipiravir in India, we continue to innovate and seek new treatment options for COVID-19 patients. Introducing this higher strength of FabiFlu is in line with these efforts to ensure a smoother experience for patients, by reducing their daily pill burden.”

“The 200 mg dosage of FabiFlu was developed in line with global formulations of the drug favipiravir, which had similar strength. The 400 mg version is a result of Glenmark’s own R&D efforts to improve treatment experience for patients in India,” she added.

Glenmark has also commenced a post marketing surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in a large pool of patients prescribed with the oral antiviral favipiravir, as part of an open label, multicenter, single arm study.